Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGM vs PVA for Arterioportal Shunts in HCC TACE
NCT02338297Phase 3Unknown
- Sponsor
- Nanjing Medical University
- Start
- Feb 2016
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of ethanol in hepatocellular carcinoma (HCC) (2 arms), sponsored by Nanjing Medical University. Primary endpoints: Overall Survival at 3 years and Arterioportal Shunt Improvement at 2 months. Status: unknown.
02
Drugs
ethanol
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02338297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02338297.